Company News
Praxis Stock Falls 7% After FDA Delay
Praxis Precision Medicines (NASDAQ: PRAX) shares dropped about 7% in after‑hours trading following an FDA extension of its relutrigine review.
The FDA set a new PDUFA target action date of December 27
